19:38 , Jul 9, 2019 |  BC Extra  |  Company News

In Lysando’s Artilysin tech, AiCuris sees means to evade antibiotic resistance

AiCuris believes it can bypass antibiotic resistance by using Lysando's platform to develop an array of phage-derived antibacterial proteins spanning broad and narrow spectrum activity. AiCuris Anti-infective Cures GmbH (Wuppertal, Germany) will gain exclusive, worldwide...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
01:37 , Aug 10, 2018 |  BC Innovations  |  Finance

Super-sized ambitions

A trend toward super-sized initial financings is attracting a new set of deep-pocketed investors to the early stage space. These new players are making earlier commitments with hopes of guaranteeing larger ownership positions at an...
19:51 , Apr 20, 2018 |  BC Week In Review  |  Company News

AiCuris, Max Planck partner to develop anti-infectives

AiCuris Anti-infective Cures GmbH (Wuppertal, Germany) partnered with the Max Planck Institute of Molecular Physiology (Dortmund, Germany) to develop new compounds to treat viral and bacterial infections. AiCuris will gain access to the institute's proprietary...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
00:58 , Nov 16, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends Merck's Prevymis for CMV

EMA's CHMP recommended approval of oral and IV formulations of Prevymis letermovir (MK-8228; AIC246) from Merck & Co. Inc. (NYSE:MRK) to prevent cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic...
23:32 , Nov 10, 2017 |  BC Extra  |  Company News

CHMP recommends basket of therapies

EMA's CHMP recommended approval of a host of therapies, including Fasenra benralizumab to treat asthma, Adynovi for hemophilia A and Prevymis letermovir (MK-8228) to prevent cytomegalovirus (CMV) infection. CHMP backed approval of Fasenra from AstraZeneca...
20:44 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

FDA approves Merck's Premyvis letermovir for CMV

FDA approved once-daily oral and IV formulations of Prevymis letermovir (MK-8228) from Merck & Co. Inc. (NYSE:MRK) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation (HSCT). The approval...
20:20 , Nov 9, 2017 |  BC Extra  |  Company News

FDA approves Merck's Prevymis for CMV

FDA approved once-daily oral and IV formulations of Prevymis letermovir (MK-8228) from Merck & Co. Inc. (NYSE:MRK) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation (HSCT). The approval...